CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting

Main Article Content

Guilherme Rabinowits
a:1:{s:5:"en_US";s:106:"Department of Hematology and Oncology, Miami Cancer Institute/Baptist Health South Florida, Miami, FL, USA";}

Jade Homsi
Soo Park
Nikhil Khushalani
Timothy Panella
David Ellison
Rhonda Gentry
Suraj Venna
John Strasswimmer
Richard Zuniga
Sunandana Chandra
Emily Ruiz
Michael Migden
Sherrif Ibrahim
Nikita Mehta
Timothy Inocencio
Xuanyao He
Haixin Zhang
Kathryn Gillis
Jean-Francois Pouliot

Keywords

cemiplimab

References

1. de Jong E et al. J Eur Acad Derm Venereol. 2021;36(Suppl. 1):6–10.

2. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

3. Regeneron Pharmaceuticals, Inc. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf [Accessed Jul 9, 2022].

4. European Medicines Agency. LIBTAYO® EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo [Accessed Jul 25, 2022].

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.174

Article Details

How to Cite
[1]
Rabinowits, G., Homsi, J. , Park, S., Khushalani, N. , Panella, T. , Ellison, D., Gentry, R., Venna, S., Strasswimmer, J., Zuniga, R. , Chandra, S. , Ruiz, E., Migden, M., Ibrahim, S., Mehta, N. , Inocencio, T. , He, X., Zhang, H., Gillis, K. and Pouliot, J.-F. 2023. CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s174. DOI:https://doi.org/10.25251/skin.7.supp.174.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 > >>